Why the study?
Does genetic deletion of the TREK-1 potassium channel prevent pressure overload-induced cardiac dysfunction and fibrosis in preclinical models?
Does genetic deletion of the TREK-1 potassium channel prevent pressure overload-induced cardiac dysfunction and fibrosis in preclinical models?
Inhibition of the TREK-1 potassium channel in cardiac fibroblasts may serve as a potential therapeutic strategy to prevent pressure overload-induced cardiac dysfunction and fibrosis.
May support fibroblast TREK-1 inhibition to limit fibrosis; leaves open translation beyond this animal model.
Cardiac two-pore domain potassium channels (K2P) exist in organisms from Drosophila to humans; however, their role in cardiac function is not known. We identified a K2P gene, CG8713 (sandman), in a Drosophila genetic screen and show that sandman is critical to cardiac function. Mice lacking an ortholog of sandman, TWIK-related potassium channel (TREK-1, also known Kcnk2), exhibit exaggerated pressure overload-induced concentric hypertrophy and alterations in fetal gene expression, yet retain preserved systolic and diastolic cardiac function. While cardiomyocyte-specific deletion of TREK-1 in response to in vivo pressure overload resulted in cardiac dysfunction, TREK-1 deletion in fibroblasts prevented deterioration in cardiac function. The absence of pressure overload-induced dysfunction in TREK-1-KO mice was associated with diminished cardiac fibrosis and reduced activation of JNK in cardiomyocytes and fibroblasts. These findings indicate a central role for cardiac fibroblast TREK-1 in the pathogenesis of pressure overload-induced cardiac dysfunction and serve as a conceptual basis for its inhibition as a potential therapy.
No takes yet. Share an insight, caveat, or question.
Abraham et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: